Magnus Financial Group LLC Invests $276,000 in Capricor Therapeutics Inc (NASDAQ:CAPR)

Magnus Financial Group LLC purchased a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR) in the 4th quarter, HoldingsChannel.com reports. The fund purchased 20,000 shares of the biotechnology company’s stock, valued at approximately $276,000.

A number of other large investors have also recently bought and sold shares of the business. Krilogy Financial LLC acquired a new position in Capricor Therapeutics in the fourth quarter valued at $287,000. JPMorgan Chase & Co. boosted its stake in shares of Capricor Therapeutics by 419.5% during the third quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company’s stock worth $855,000 after buying an additional 45,381 shares during the period. Virtu Financial LLC purchased a new position in shares of Capricor Therapeutics during the third quarter worth about $458,000. Barclays PLC increased its position in Capricor Therapeutics by 106.6% in the 3rd quarter. Barclays PLC now owns 36,296 shares of the biotechnology company’s stock valued at $552,000 after acquiring an additional 18,724 shares during the period. Finally, Sphera Funds Management LTD. acquired a new position in Capricor Therapeutics in the 3rd quarter valued at about $938,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Stock Up 6.0 %

Shares of CAPR stock opened at $14.90 on Thursday. The business’s fifty day moving average price is $15.22 and its 200 day moving average price is $11.75. Capricor Therapeutics Inc has a 1-year low of $3.52 and a 1-year high of $23.40.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research note on Thursday, January 2nd. Cantor Fitzgerald increased their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Maxim Group boosted their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Finally, Piper Sandler assumed coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price for the company. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.